Antikor is a biotechnology company developing next-generation oncology treatments based on antibody fragment drug conjugates. Its proprietary OptiLink platform uses smaller, fully human antibody fragments linked to potent drug payloads, aiming to improve tumour penetration, speed normal tissue clearance and widen the therapeutic window compared with conventional antibody drug conjugates. The company focuses on difficult-to-treat solid tumours, including gastrointestinal cancers, and combines antibody engineering, linker-payload chemistry and preclinical drug development.
This is a company profile stub. Create an account to claim your profile.
Industry
BiotechnologyAreas of Focus
Location
London
Status
Active
